Halozyme Therapeutics (HALO) Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HALO shares.
View HALO analyst ratings or view top-rated stocks.

11 equities research analysts have issued 1 year target prices for Halozyme Therapeutics' stock. Their HALO share price forecasts range from $42.00 to $68.00. On average, they expect the company's share price to reach $54.27 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price.
View analysts price targets for HALO or view top-rated stocks among Wall Street analysts.

Halozyme Therapeutics' stock was trading at $56.90 at the start of the year. Since then, HALO stock has decreased by 30.5% and is now trading at $39.57.
View the best growth stocks for 2023 here.

Halozyme Therapeutics saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 6,840,000 shares, a decrease of 6.3% from the August 15th total of 7,300,000 shares. Based on an average daily volume of 1,030,000 shares, the short-interest ratio is currently 6.6 days. Approximately 5.2% of the shares of the company are short sold.
View Halozyme Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our HALO earnings forecast.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.09. The biopharmaceutical company had revenue of $221.04 million for the quarter, compared to analysts' expectations of $201.91 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 254.75% and a net margin of 30.21%.

ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Long/Short ETF (FFLS), Future Fund Active ETF (FFND), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), BlackRock Future Innovators ETF (BFTR), Invesco S&P MidCap 400 Pure Growth ETF (RFG), SPDR S&P Biotech ETF (XBI) and Goldman Sachs Future Health Care Equity ETF (GDOC).

Halozyme Therapeutics issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of $2.65-$2.75 for the period, compared to the consensus earnings per share estimate of $2.61. The company issued revenue guidance of $825.00 million-$845.00 million, compared to the consensus revenue estimate of $823.06 million.

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Halozyme Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Artisan Partners Limited Partnership (5.66%), Snyder Capital Management L P (3.28%), Geode Capital Management LLC (2.07%), Marshall Wace LLP (1.76%), Thrivent Financial for Lutherans (1.58%) and Northern Trust Corp (1.53%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends.

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HALO stock can currently be purchased for approximately $39.57.

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $5.22 billion and generates $660.12 million in revenue each year. The biopharmaceutical company earns $202.13 million in net income (profit) each year or $1.71 on an earnings per share basis.

The company employs 393 workers across the globe.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.